Geographic Atrophy Overview

Save information for later
Sign Up

Learn About Geographic Atrophy

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Geographic Atrophy Local Doctors?
Richard F. Spaide
Elite in Geographic Atrophy
Ophthalmology
Elite in Geographic Atrophy
Ophthalmology

Vitreous Retina Macula Consultants Of New York(Downtown)

110 Lafayette St, Suite 502, 
New York, NY 
Languages Spoken:
English

Richard Spaide is an Ophthalmologist in New York, New York. Dr. Spaide is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Central Serous Chorioretinopathy, and Vitrectomy.

Elite in Geographic Atrophy
Ophthalmology
Elite in Geographic Atrophy
Ophthalmology
2100 Erwin Rd, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Cynthia Toth is an Ophthalmologist in Durham, North Carolina. Dr. Toth is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. Her top areas of expertise are Retinopathy of Prematurity, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Trabeculectomy. Dr. Toth is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Ursula M. Erfurth-Schmidt
Elite in Geographic Atrophy
Elite in Geographic Atrophy
Vienna, AT 

Ursula Erfurth-Schmidt practices in Vienna, Austria. Ms. Erfurth-Schmidt is rated as an Elite expert by MediFind in the treatment of Geographic Atrophy. Her top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal.

What are the latest Geographic Atrophy Clinical Trials?
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration

Summary: The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

Summary: A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration